# A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

> **NCT00405756** · PHASE3 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 459 (actual)

## Conditions studied

- Newly Diagnosed Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide: Double-blind Induction
- **DRUG:** Melphalan
- **DRUG:** Prednisone
- **DRUG:** Aspirin
- **DRUG:** Placebo
- **DRUG:** Lenalidomide: Double-blind Maintenance
- **DRUG:** Lenalidomide: Open-label

## Key facts

- **NCT ID:** NCT00405756
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-11
- **Final completion:** 2016-04
- **Target enrollment:** 459 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405756, "A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00405756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*